Search Results

You are looking at 1 - 10 of 60 items for :

  • "infliximab" x
Clear All
Orvosi Hetilap
Authors: Nóra Gyöngyösi, Kende Lőrincz, Sarolta Kárpáti and Norbert Wikonkál

Atteno, M., Peluso, R., Costa, L., et al.: Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs. Clin

Open access
Orvosi Hetilap
Authors: Gábor Veres, Dolóresz Szabó, Ágnes Várkonyi, Beáta Tari, Marianne Polgár, Judit B. Kovács, Ágnes Horváth, Erika Tomsits, István Tokodi, Hedvig Bodánszky, Antal Dezsőfi, Erzsébet Szakos, Noémi Vass, Viktória Ruszinkó, Márta Kovács, Katalin Eszter Müller and András Arató

. 2002 252 475 496 Veres, G., Baldassano, R. N., Mamula, P.: Infliximab therapy in children and adolescents

Open access
Orvosi Hetilap
Authors: Gábor Veres, Réka Putz, Dolóresz Szabó, Kriszta Molnár, Hedvig Bodánszky, Antal Dezsőfi and András Arató

282 287 Veres, G., Baldassano, R. N., Mamula, P.: Infliximab therapy in children and adolescents with inflammatory bowel disease. Drugs, 2007, 67 , 1703

Open access
Orvosi Hetilap
Authors: Tamás Molnár, Klaudia Farkas, Tibor Nyári, Zoltán Szepes, Ferenc Nagy, Tamás Kiss and Tibor Wittmann

Hanauer, S. B., Feagan, B. G., Lichenstein, G. R. és mtsai: Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet, 2002, 359 , 1541

Restricted access

. 1993 30 1443 1453 Chaudhary, R., Ghosh, S.: Prediction of response to infliximab in Crohn’s disease

Restricted access
Orvosi Hetilap
Authors: Péter László Lakatos and László Lakatos

470 474 Mouser, J. F., Hyams, J. S.: Infliximab: a novel chimeric monoclonal antibody for the treatment of Crohn’s disease. Clin. Ther., 1999, 21 , 932

Restricted access
Orvosi Hetilap
Authors: Péter Bacsur, Soma Skribanek, Ágnes Milassin, Klaudia Farkas, Renáta Bor, Anna Fábián, Mariann Rutka, Anita Bálint, Kata Judit Szántó, Tibor Tóth, Ferenc Nagy, Zoltán Szepes, Krisztina Boda and Tamás Molnár

Bálint A, Rutka M, Végh Z, et al. Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: results from Central European nationwide cohort. Expert

Open access

. és mtsai: Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med., 2005, 353 , 2462–2476. Feagan B. G. Infliximab for induction and

Restricted access
Journal of Flow Chemistry
Authors: Meaghan M. Sebeika, Nicholas G. Gedeon, Sara Sadler, Nicholas L. Kern, Devan J. Wilkins, David E. Bell and Graham B. Jones

Interest in the field of antibody—drug conjugates (ADCs) has grown exponentially over the past decade. As the product pipeline grows, there is increasing need for robust chemistries which allow selective and efficient functionalization of the antibody cores for introduction of appropriate linkers and spacer groups. Under conventional bioconjugation conditions, product heterogeneity often results, and the drug-to-antibody ratios (DAR) are inconsistent. Based on our experience in protein derivatization, we have investigated the potential for continuous-flow microreactor technology to expedite and facilitate such processes. We demonstrate its potential using reagent proteins and the chimeric monoclonal antibody infliximab (Remicade™).

Restricted access
Orvosi Hetilap
Authors: Renáta Bor, Klaudia Farkas, Anita Bálint, Mónika Szűcs, Szabolcs Ábrahám, Gellért Baradnay, Tibor Wittmann, Zoltán Szepes, Ferenc Nagy and Tamás Molnár

Crohn’s disease treated with infliximab. Clin. Gastroenterol. Hepatol., 2013, 11 , 975–981. e1–4. Gizard E. Long-term outcome of perianal fistulizing Crohn’s disease treated with

Restricted access